Nicox reports six-month revenues from AdenoPlus

Ophthalmic company Nicox reported revenues of €0.2 million for the six months ended June 30, 2013, compared to €7.5 million for the same period of 2012.

The French company’s revenues during the first half of 2013 correspond to the sales of AdenoPlus, a point-of-care diagnostic test for adenovirus licensed from Rapid Pathogen Screening, Inc., in June 2012. Revenues recognized in the first six months of 2012 correspond to a milestone payment of $10 million Nicox received from Bausch & Lomb in April 2012, following Bausch & Lomb’s decision to continue the development of latanoprostene bunod.

“We have made good progress in the expansion of our product pipeline during the first six months of the year, with the addition of an innovative line of four eye care products licensed from an European partner for Europe, Middle East and Africa planned to be launched in the first quarter of 2014, and a proprietary dry eye panel for the diagnosis of Sjögren’s syndrome from Immco Diagnostics under a promotion agreement for North America and an option for the rest of the world,” said Michele Garufi, chairman and CEO of Nicox.

She adds: “As planned, Bausch & Lomb has initiated its pivotal Phase 3 studies for latanoprostene bunod. This compound is a major asset of our pipeline and further demonstrates the value of Nicox’s NO-donating research platform as an innovative therapeutic approach in ophthalmology.”